Adapsyn Bioscience Inks Collaboration Pact With Evotec

Author: Vandana Singh | September 21, 2022 10:06am

• Adapsyn Bioscience Inc, a chemical bioinformatics company, announced a strategic collaboration with Evotec SE (OTC:EVOTF) (NASDAQ:EVO).
• Under the collaboration, Evotec will have the opportunity to evaluate small molecules developed by Adapsyn as potential therapeutic candidates in proprietary and partnered drug discovery projects.
• The Adapsyn platform uses artificial intelligence and machine learning to identify and isolate novel drug-like metabolites from microbes for downstream assay and development. 
• Related: Evotec, Alpine Expand Pact For Commercial Process Development Of Autoimmune Disease Candidate.
• Evotec has extensive biochemical, cellular, and phenotypic screening capabilities, and particular expertise in natural product drug discovery and development. 
• The multi-year collaboration will provide Evotec with libraries of bioactive small molecules to screen against high-value targets of interest to Evotec and its partners. 
• Adapsyn will be responsible for library generation and compound production efforts.
• Price Action: EVO shares are down 0.74% at $9.35 on the last check Wednesday.

Posted In: EVO EVOTF